［1］Kau P, Nagaraja GM, Zheng H, et al. A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease ［J］. BMC Cancer, 2012, 12: 120.
［2］Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer［J］. Cancer, 2007, 109 (1): 25-32.
［3］Rakha EA, Putti TC, Abd El-Rehim DM, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation［J］. J Pathol, 2006, 208(4): 495-506.
［4］Weigelt B, Kreike B, Reis-Filho J. Metaplastic breast carcinomas are basalike breast cancers: a genomic profiling analysis［J］. Breast Cancer Res Treat, 2009, 117(2): 273-280.
［5］Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell［J］. Nat Med, 1997, 3(7): 730-737.
［6］Clarke J, Lodie TA, Blickarz CE, et al. Systematic analysis of re-portedly distinct populations of multipotent bone marrow-derived stem cells reveals a lack of distinction［J］. Tissue Eng, 2002, 8(5): 739-751.
［7］Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells［J］. Proc Natl Acad Sci USA, 2003, 100(7): 3983-3988.
［8］Honeth G, Bendahl PO, Ringnér M, et al. The CD44⁺ /CD24^-pheno-type is enriched in basal-like breast tumors［J］. Breast Cancer Res, 2008, 10(3): R53.
［9］Tiezzi DG,  Valejo FA, Marana HR, et al. CD44⁺ /CD24^- cells and lymph node metastasis in stage I and II invasive ductal carcinoma of the breast［J］. Med Oncol, 2012,29(3):1479-1485.
［10］Fillmore C, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy［J］. Breast Cancer Res, 2008, 10(2): R25 
［11］Schmitt F,  Ricardo S, Vieira AF, et al. Cancer stem cell markers in breast neoplasias: their relevance and distribution in distinct molecular subtypes［J］. Virchows Arch, 2012, 460(6): 545-553.
［12］Li HH. Isolation and identification of triple negative breast cancer stem cells and the preliminary research on the biological behaviours［D］. Beijing: Peking Union Medical College, Doctoral Dissertation, 2012:1-74. (in Chinese)
李慧慧. 三阴性乳腺癌干细胞的分离、鉴定及生物学行为的初步研究［D］. 北京:北京协和医学院博士学位论文, 2012:1-74. 
［13］Wei SJ, Li HF, Liu YB, et al. Influence of chemotherapy on CD44+CD24-/low cell subpopulation of triple-negative breast cancer［J］. Tumor, 2011, 31 (11): 1016-1021. (in Chinese)
魏素菊，李海飞，刘义冰, 等. 化疗对三阴性乳腺癌CD44+CD24-/low细胞亚群的影响［J］. 肿瘤, 2011, 31 (11): 1016-1021. 
［14］Matthew JG, Lucienne C, Konstantinos P, et al. Mammosphere cul-ture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells［J］. Breast Cancer Res, 2008, 10(3): R52. (in Chinese)
［15］Jia M, Wei SJ. Research progress in breast cancer stem cells and its clinical significance［J］. Journal of Chinese Oncology, 2011, 3(17): 161-164. （in Chinese）
贾明, 魏素菊. 乳腺癌干细胞的研究进展及其临床意义［J］. 肿瘤学杂志, 2011, 3(17): 161-164. 
［16］Vermeulen L, Todaro M, de Sousa Mello F, et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity ［J］. Proc Natl Acad Sci USA, 2008, 105(36): 13427-13432．
［17］Cailleau R, Young R, Olive M, et al. Breast tumor cell lines from pleural effusions ［J］. J Natl Cancer Inst, 1974, 53(3): 661-674.
［18］Liu B, Fan Z, Edgerton SM, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells［J］. Cell Cycle, 2009, 8(13): 2031-2040.
［19］Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew,give rise to phenotypically diverse progeny and survive chemotherapy［J］. Breast Cancer Res, 2008, 10(2): R25.
［20］Stratford AL, Reipas K, Maxwell C, et al. Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer［J］. Expert Rev Mol Med, 2010,  12: e22.
［21］Geng J, Zhang J, Han ZhX, et al. The thalidomide interventions for triple negative breast cancer stem cell mammospheres［J］. The Journal of Practical Medicine, 2012, 28(3): 361-363. (in Chinese)
耿杰, 张洁, 韩正祥, 等. 沙利度胺对三阴性乳腺癌干细胞微球体的干预研究［J］. 实用医学杂志, 2012, 28(3): 361-363. 
［22］Omene CO, Wu J,  Frenkel K. Caffeic acid phenethyl ester (CAPE) derived from propolis, a honeybee product, inhibits growth of breast cancer stem cells ［J］. Invest New Drugs, 2012, 30(4): 1279-1288.
［23］Prud′homme GJ,  Glinka Y, Toulina A, et al. Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist［J］. PLoS One, 2010, 5(11): e13831. 
［24］Raouf A, Zhao Y, To K, et al. Transcriptome analysis of the normal human mammary cell commitment and differentiation process［J］. Cell Stem Cell, 2008, 3(1): 109-118.
［25］Qiu M, Peng Q, Jiang I, et al. Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells［J］. Cancer Lett, 2013, 328(2):261-270.
［26］Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer: Ready for clinical application［J］? J Clin Oncol, 2005, 23(29):7350-7360.
［27］Arima Y, Hayashi N, Hayashi H, et al. Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer［J］. Int J Cancer, 2012, 130(11): 2568-2579.
［28］Yin S, Xu L, Bandyopadhyay S, et al. Cisplatin and TRAIL enhance breast cancer stem cell death［J］. Int J Oncol, 2011, 39(4): 891-898.
［29］Liu J,  Lu KH, Liu Zl, et al. MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1［J］. BMC Cancer, 2012, 12: 519.
［30］Hu K,  Law JH,  Fotovati A, et al. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells ［J］. Breast Cancer Res, 2012, 14: R22.
［31］Liu C,  Cao X, Zhang Y, et al. Co-expression of Oct-4 and Nestin in human breast cancers［J］. Mol Biol Rep, 2012, 39(5):5875-5881. 